Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma

Br J Haematol. 2024 Jun;204(6):2222-2226. doi: 10.1111/bjh.19371. Epub 2024 Feb 29.

Abstract

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linked datasets on hospital admissions, Systemic Anti-Cancer Therapy, socio-demographics, comorbidities and death, identifying cases from 1 January 2013 to 31 December 2019 with survival data up to 5 January 2021. Crude and directly age-standardised incidence rates per million persons per year were calculated. Crude and adjusted incidence rate ratios compared incidence between groups using Poisson regression. A Cox proportional hazards model estimated mortality risks adjusted for age, sex, ethnicity, deprivation and allogenic stem cell transplant (allo-SCT; time varying). We identified 44 patients, mean age 42 years. Median survival was 11 months, and 1 and 5 year survivals were 48% (95% CI 29%-43%) and 22% (95% CI 12%-42%) respectively. The age-standardised incidence was 0.1 per million/year. Incidence was higher in areas with greater deprivation (0.15 per million/year), and more cases than expected were in non-White patients (39%). Non-Whites had a twofold increased risk of death (adjusted hazard ratio 2.21 [95% CI 1.03-4.78]) even after adjusting for deprivation, younger age and allo-SCT. In conclusion, ethnicity and socio-economic status affect both the incidence and survival of HSTCL.

Keywords: deprivation; ethnicity; hepatosplenic lymphoma.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • England / epidemiology
  • Ethnicity / statistics & numerical data
  • Female
  • Humans
  • Incidence
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / mortality
  • Liver Neoplasms / therapy
  • Lymphoma, T-Cell* / epidemiology
  • Lymphoma, T-Cell* / mortality
  • Lymphoma, T-Cell* / therapy
  • Male
  • Middle Aged
  • Social Class
  • Splenic Neoplasms* / epidemiology
  • Splenic Neoplasms* / mortality
  • Young Adult